IRIS
LANDI, DORIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.000
AS - Asia 2.643
EU - Europa 1.883
SA - Sud America 399
AF - Africa 33
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 10.966
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.927
SG - Singapore 1.208
IT - Italia 854
CN - Cina 331
BR - Brasile 329
RU - Federazione Russa 312
HK - Hong Kong 270
BD - Bangladesh 208
VN - Vietnam 201
IE - Irlanda 196
KR - Corea 176
JP - Giappone 102
DE - Germania 97
NL - Olanda 71
FR - Francia 70
GB - Regno Unito 66
CA - Canada 45
FI - Finlandia 36
UA - Ucraina 36
IN - India 28
AT - Austria 27
AR - Argentina 26
SE - Svezia 26
IQ - Iraq 19
TR - Turchia 19
CH - Svizzera 18
ES - Italia 15
PL - Polonia 15
EC - Ecuador 14
PK - Pakistan 12
ZA - Sudafrica 12
GR - Grecia 11
ID - Indonesia 11
MX - Messico 11
MY - Malesia 10
EG - Egitto 9
CO - Colombia 8
CZ - Repubblica Ceca 8
CL - Cile 7
PY - Paraguay 7
UZ - Uzbekistan 7
KG - Kirghizistan 6
RS - Serbia 6
IR - Iran 5
RO - Romania 5
AU - Australia 4
AZ - Azerbaigian 4
PE - Perù 4
PH - Filippine 4
SA - Arabia Saudita 4
MA - Marocco 3
PA - Panama 3
VE - Venezuela 3
AL - Albania 2
BB - Barbados 2
DK - Danimarca 2
DZ - Algeria 2
HN - Honduras 2
JO - Giordania 2
KE - Kenya 2
NG - Nigeria 2
NI - Nicaragua 2
PT - Portogallo 2
QA - Qatar 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BS - Bahamas 1
BY - Bielorussia 1
CY - Cipro 1
DM - Dominica 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
GD - Grenada 1
GE - Georgia 1
GI - Gibilterra 1
GT - Guatemala 1
JM - Giamaica 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LT - Lituania 1
MM - Myanmar 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PR - Porto Rico 1
SI - Slovenia 1
TJ - Tagikistan 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
Totale 10.966
Salva come PNG Salva come JPEG
Città #
Wilmington 1.234
Houston 972
Singapore 649
Woodbridge 527
New York 392
San Jose 373
Hong Kong 267
Chandler 198
Fairfield 179
Ashburn 177
Dublin 177
Beijing 135
Rome 110
Santa Clara 99
Los Angeles 92
Tokyo 90
The Dalles 83
Ho Chi Minh City 75
Dallas 71
Milan 71
Ann Arbor 65
Council Bluffs 63
Seattle 61
Buffalo 58
Medford 57
Roebling 55
Moscow 53
Cambridge 50
Hanoi 45
North Bergen 43
São Paulo 39
Lauterbourg 36
Naples 36
Dearborn 29
Lawrence 28
Turin 26
Chicago 21
Lappeenranta 19
San Diego 19
Nuremberg 17
Bologna 16
Redondo Beach 16
Colorado Springs 15
Jacksonville 15
Palermo 13
Piove di Sacco 13
Creede 12
London 12
Vienna 12
Florence 11
Frankfurt am Main 11
Haiphong 11
Montreal 11
Munich 11
San Francisco 11
Tampa 11
Toronto 11
Brooklyn 10
Helsinki 10
Jakarta 10
Orem 10
Seoul 10
Warsaw 10
Bari 9
Belo Horizonte 9
Elk Grove Village 9
Mülheim 9
Palo Alto 9
Atlanta 8
Brno 8
Denver 8
Genoa 8
Inverigo 8
Norwalk 8
Paris 8
Redwood City 8
Salt Lake City 8
Da Nang 7
Johannesburg 7
Kuala Lumpur 7
Manchester 7
Phoenix 7
Rio de Janeiro 7
Verona 7
Amsterdam 6
Belgrade 6
Boardman 6
Brasília 6
Chennai 6
Erbil 6
Lodi 6
Mexico City 6
Nanjing 6
Philadelphia 6
Sterling 6
Zhengzhou 6
Athens 5
Bergamo 5
Billings 5
Bogotá 5
Totale 7.321
Salva come PNG Salva come JPEG
Nome #
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML 515
TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis 506
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 445
Validity of the Italian multiple sclerosis neuropsychological screening questionnaire 374
Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course 366
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis 340
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 330
Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis 321
Safety, tolerability and effectiveness of dimethyl fumarate in multiple sclerosis: an independent, multicenter, real-world study 318
Miscarriage induces reactivation of inflammation in relapsing-remitting multiple sclerosis 317
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study 311
null 289
Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis 206
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 184
Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis 182
Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study 181
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab 178
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression 172
Functional assessment of outer and middle macular layers in multiple sclerosis 167
Anti-HBs titers are not decreased after treatment with oral Cladribine in patients with Multiple Sclerosis vaccinated against Hepatitis B virus 144
T-cell responses to SARS-CoV-2 in Multiple Sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-Spike antibody titers 140
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications 136
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab 135
Assessment of macular function by multifocal electroretinogram in patients with multiple sclerosis treated with fingolimod 124
Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis 120
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 116
Correction to: Validity of the Italian multiple sclerosis neuropsychological screening questionnaire 111
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 110
Maternal Multiple Sclerosis and Offspring’s Developmental and Behavioral Profile: A Case-control Study 108
Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis 107
Multifocal Electroretinogram Photopic Negative Response: A Reliable Paradigm to Detect Localized Retinal Ganglion Cells' Impairment in Retrobulbar Optic Neuritis Due to Multiple Sclerosis as a Model of Retinal Neurodegeneration 103
COVID-19: dealing with a potential risk factor for chronic neurological disorders 100
Cortical ischemic lesion burden measured by DIR is related to carotid artery disease severity 97
Patient's point of view on the use of telemedicine in multiple sclerosis: a web-based survey 96
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) in the Italian population 93
Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study 90
Complex epileptic palilalia: a case report 90
Cognition is related to resting-state small-world network topology: an magnetoencephalographic study 88
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 87
What happens after fingolimod discontinuation? A multicentre real-life experience 87
Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment 86
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis 86
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 85
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty 80
A specific anti-COVID-19 BNT162b2 vaccine-induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients 80
Association of vitamin D serum levels and vitamin D supplementation with B cell kinetics and disease activity in Multiple Sclerosis patients treated with ocrelizumab: an Italian multi-center study 80
Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection 79
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 75
Diagnostic value of JC polyomavirus viruria, viremia, serostatus and microRNA expression in multiple sclerosis patients undergoing immunosuppressive treatment 74
Intra-cortical connectivity in multiple sclerosis: a neurophysiological approach 70
Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability 70
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT) 70
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis 70
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy 70
Cerebral restorative plasticity from normal ageing to brain diseases: a "never ending story" 69
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis 69
Cortico-muscular coherence as an index of fatigue in multiple sclerosis 68
A disease-specific convergence of host and Epstein-Barr virus genetics in multiple sclerosis 68
Phenotypic characterization of the placenta from women with Multiple Sclerosis exposed to Natalizumab during pregnancy. 67
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study 67
Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography 66
Diffusion-weighted lesions after carotid artery stenting are associated with cognitive impairment 66
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 65
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study 64
Thalamocortical sensorimotor circuit in multiple sclerosis: an integrated structural and electrophysiological assessment 63
Gender-related differences in functional connectivity in multiple sclerosis 63
Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability 63
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 63
Skin Thickening of the Scalp and High Signal Intensity of Dentate Nucleus in Multiple Sclerosis: Association With Linear Versus Macrocyclic Gadolinium-Based Contrast Agents Administration 63
Ovarian reserve in patients with multiple sclerosis: A systematic review and meta-analysis 61
Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol 58
COVID-19 vaccine hesitancy among Italian people with multiple sclerosis 58
Sex effects across the lifespan in women with multiple sclerosis 57
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 55
fMRI-vs-MEG evaluation of post-stroke interhemispheric asymmetries in primary sensorimotor hand areas 55
Sars-CoV2 infection in pregnant women with multiple sclerosis 55
Structural and Functional Assessment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes Without History of Optic Neuropathy 55
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders 54
Treatment modifiers across different regimens of natalizumab treatment in MS: an Italian real-world experience 51
Therapeutic choices and disease activity after 2 years of treatment with cladribine: an Italian multicenter study (CladStop) 50
Topographical Correlation between Structural and Functional Impairment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes with a History of Optic Neuropathy 49
Optimizing the "Time to pregnancy" in women with multiple sclerosis: the OPTIMUS Delphi survey 49
Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing???remitting multiple sclerosis 49
Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue." 49
Dorsolateral medullary ischemic infarction causing autonomic dysfunction and headache: a case report 46
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 46
Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine 42
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis 41
Functional connectivity changes in multiple sclerosis patients: a graph analytical study of MEG resting state data 40
Exposure to natalizumab during pregnancy and lactation is safe - Yes 40
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 36
Treatment discontinuation in older patients with multiple sclerosis 31
Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue." 29
null 5
null 3
Totale 11.207
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.020
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.020
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202117 0 0 0 0 0 0 0 0 0 0 0 17
2021/2022379 29 28 20 40 23 48 14 22 34 27 23 71
2022/20231.104 38 30 286 193 48 178 119 47 74 12 59 20
2023/2024451 101 10 22 23 32 64 35 12 28 23 11 90
2024/20252.078 61 375 180 142 62 212 144 88 220 273 180 141
2025/20263.697 274 214 397 199 324 99 493 421 392 272 338 274
Totale 11.207